louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05728528: Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients
Official title: Impact of Moderate to Vigorous-intensity Physical Activities on Pharmacokinetic-guided Extended Half-life FVIII Concentrates Prophylaxis Severe Hemophilia A Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hemophilia
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2023-02-15
Enrollment: 13
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: To compare clinical outcomes before and after using combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis in moderate to severe hemophilia A patients

Detailed description: This is a prospective cohort study of severe hemophilia A patients receiving low-dose EHL FVIII concentrates with PK-guided EHL FVIII concentrates prophylaxis alone for 6 months. Additional exercise workshops from sport scientists were introduced individually to this group of patients along with using the same prophylaxis method for another period of 6 months. The annualized bleeding rates (ABR), the annualized joint bleeding rates (AJBR), the haemophilia-specific quality-of-life (Haemo-QoL-A) scores, the hemophilia Joint Health Scores (HJHS) and skeletal muscle mass were compared between these two periods

Eligibility criteria: Inclusion Criteria:

* Severe Hemophilia A patients

Exclusion Criteria:

-

Primary outcomes:
measure: annualized bleeding rates (ABR)
timeFrame: 6 months
measure: annualized joint bleeding rates (AJBR)
timeFrame: 6 months
measure: haemophilia-specific quality-of-life (Haemo-QoL-A) scores
timeFrame: 6 months
measure: hemophilia Joint Health Scores (HJHS)
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: King Chulalongkorn Memorial Hospital
Study officials:
References:
Clinical trial NCT03283228: Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Official title: Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Adult Acute Myeloid Leukemia
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-09-14
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Anew diagnosis cases of adult AML

Brief summary: 1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML.
2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.

Detailed description: 1. CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could predict a poor prognosis for AML patients.
2. CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely related to the prognosis of AML patients

Eligibility criteria: Inclusion Criteria:

Anew diagnosis cases of adult AML

Exclusion Criteria:

1. Pediatric AML .
2. follow up cases of adult AML

Primary outcomes:
measure: CD11b and CD56 marker
timeFrame: 24 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00000228: Buprenorphine Detox With Two Types of Treatment. BBD I - 10
Official title: Buprenorphine Detox With Two Types of Treatment. BBD I
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Opioid-Related Disorders
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: University of Vermont
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare overall treatment outcome between behavioral versus standard treatment types.


Eligibility criteria: Please contact site for information.

Primary outcomes:
measure: Drug use
measure: Retention
measure: Weeks abstinent
measure: Weeks continuous abstinence
measure: Overall treatment outcome
Secondary outcomes:
Other outcomes:
Locations:
city: Burlington
country: United States
facility: Treatment Research Center
state: Vermont
Study officials:
affiliation: University of Vermont
name: Warren Bickel, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bickel WK, Amass L, Higgins ST, Badger GJ, Esch RA. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. J Consult Clin Psychol. 1997 Oct;65(5):803-10. doi: 10.1037//0022-006x.65.5.803.
Clinical trial NCT01237028: Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers
Official title: Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: IgA Nephropathy
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2010-11-09
Enrollment: 168
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will help to show the efficacy of vitamin D and address the optimal strategy to minimize renal injury in IgAN patients.


Eligibility criteria: Inclusion Criteria:

* Biopsy-proven Ig AN patients aged 20-70 years
* Patients with residual proteinuria \> 500 mg/g creatinine despite renin-angiotensin system blockade and adequate blood pressure control for more than 3 months
* Patients who give informed consent, and 4) estimated GFR \>= 30 ml/min/1.73 m2.

Exclusion Criteria:

* patients \< 20 years or \> 70 years
* hypersensitivity to vitamin D analogs
* patients who need urgent dialysis
* hypercalcemia within 3 months (uncorrected serum calcium level \> 10.2 mg/dL)
* clinical features of rapidly progressive glomerulonephritis
* life expectancy less than 24 months
* uncontrolled hypertension
* decompensated liver or lung disease
* symptomatic heart failure (NYHA class II-IV or LVEF \< 40%)
* estimated GFR \< 30 ml/min/1.73 m2.

Primary outcomes:
measure: changes in proteinuria
timeFrame: random urine protein/creatinine ratio every 2month and 24hour urine protein every 6month
Secondary outcomes:
measure: changes in serum creatinine
timeFrame: serum creatinine every 2month
measure: changes in systolic blood pressure and diastolic pressure
timeFrame: check blood pressure at very first visit and every 2-month
measure: changes in urinary biomarkers (angiotensinogen, angiotensin II, TGF-beat, IL-6, MCP-1, TNF-alpha)
timeFrame: every 6month
measure: changes in serum 25(OH)2D3, 1,25(OH)2D3, parathyroid hormone
timeFrame: every 6month
measure: changes in serum inflammatory markers (hsCRP, IL-6)
timeFrame: every 6month
Other outcomes:
Locations:
city: Goyang
country: Korea, Republic of
facility: National Health Insurance Corporation Ilsan Hospital
city: Goyang
country: Korea, Republic of
facility: Kwandong University Myongji Hospital
city: Gunpo
country: Korea, Republic of
facility: Wongkwang University Sanbon Medical Center
city: Seongnam
country: Korea, Republic of
facility: CHA University Bundang Medical Center
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
city: Seoul
country: Korea, Republic of
facility: Ewha Womans University Medical Center
Study officials:
affiliation: Severance Hospital
name: Tae-Hyun Yoo, MD, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02776228: Treatment With Benzodiazepine After Cardiac Surgery
Official title: The Influence of Short Term Treatment With Benzodiazepine After Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Insomnia
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2016-05-18
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study deals with the prevalence of insomnia after heart surgery and the outcome of treatment with Benzodiazepine for this phenomena.

Detailed description: Patients after heart surgery develop sleep disorder in the form of Insomnia. This finding is known and described in the literature with respect to a large number of major operations such as the pneumonectomy, esophageal resection, pancreatic surgery, liver surgery and so on. In the general population, Insomnia is a common disorder and describe in more than 50% in adults over the age of 50. In patients with comorbidity among other things, heart disease indicates a rate of up to 85% of chronic insomnia. The reasons for insomnia after multiple heart surgery, including emotional stress that accompanies the patient after surgery, pain and prolonged hospitalization in the hospital. In this study, aim to compare the results of short-term treatment with sleep medication after heart surgery on morbidity and immediate recovery. This study will allow us to examine the effect of sleep medication therapy in patients receiving treatment compared to patients who did not receive treatment.

Eligibility criteria: Inclusion Criteria:

1. Age 18 and older.
2. Applicants hospital for open heart surgery

Exclusion Criteria:

1. patients who came to emergency heart surgery.
2. patients who are not hemodynamically or respiratory stable
3. Patients who were taking hypnotic drugs on a daily basis before surgery.
4. Patients with low compliance that will not be able to fill out a sleep diary
5. lactose intolerance (due to components placebo)
6. Patients who can not take medication by one or more of the following:

   * pregnant.
   * nursing.
   * Patients with severe respiratory insufficiency
   * Patients with liver failure.
   * Patients who are addicted to alcohol
   * Patients without psychiatric background.

Primary outcomes:
measure: Assessing chronic insomnia
timeFrame: 1 year
Secondary outcomes:
measure: Reducing insomnia in post cardiac surgery
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Rambam Health Care Campus
name: gil mr bolotin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01411761: Effect of Saccharomyces Boulardii on Indirect Hyperbilirubinemia and Phototherapy Duration in Very Low Birth Weight Infants
Official title: Phase 4 Study of Saccharomyces Boulardii on Indirect Hyperbilirubinemia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Indirect Hyperbilirubinemia
Keywords: indirect hyperbilirubinemia
very low birth weight infants
Lead sponsor: Zekai Tahir Burak Women's Health Research and Education Hospital
Sponsor class: OTHER
First posted: 2011-08-08
Enrollment: 80
Sex: ALL
Minimum age (years): 1
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Indirect hyperbilirubinemia is frequently observed in premature infants.Probiotics are favorable microorganisms that regulate the flora of the gastrointestinal system. In this study we aimed to compare the effect of S. boulardii on severity of hyperbilirubinemia and duration of phototherapy on very low birth weight infants.


Eligibility criteria: Inclusion Criteria:

* very low birth weight infants

Exclusion Criteria:

* chromosomal anomalies

Primary outcomes:
measure: Effect of S. boulardii on severity of hyperbilirubinemia and phototherapy duration
timeFrame: 6 months
Secondary outcomes:
measure: long term effect of S.boulardii on neurodevelopmental outcome
timeFrame: 6 months
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Zekai Tahir Burak Maternity Teaching Hospital, Division of Neonatology
Study officials:
affiliation: Zekai Tahir Burak Women's Health Research and Education Hospital
name: Gamze Demirel, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Zekai Tahir Burak Maternit Teaching Hospital
name: Ugur Dilmen, Prof
role: STUDY_DIRECTOR
References:
Clinical trial NCT03555461: Analysis of EPA® (a Food Intake Assessment Tool) as a Screening Test for Malnutrition in General Medicine
Official title: Analysis of EPA® (a Food Intake Assessment Tool) as a Screening Test for Malnutrition in General Medicine
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Malnutrition
Lead sponsor: Rennes University Hospital
Sponsor class: OTHER
First posted: 2018-06-13
Enrollment: 563
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients consulting a general practioner in his activity of substitute doctor,

Brief summary: The main objective is to evaluate the sensitivity of the EPA® for screening for malnutrition in general medicine in adults.


Eligibility criteria: Inclusion Criteria:

* To be an adult,
* Consulting the principal investigator, a general practitioner in his activity of substitute doctor,
* During the inclusion period,
* Not opposed to participating in the study.

Exclusion Criteria:

* Patients benefiting from artificial nutrition,
* Patients with advanced dementia,
* Pregnant or postpartum women,
* Patients who do not understand or speak French,
* Patients treated with diuretics who have had a change in treatment dosage during the last 6 months,
* Patients for whom weight measurement is not possible in the office (wheelchair, disability ...),
* Patients who have already been included once,
* Patients who have had surgery for obesity,
* Major persons subject to legal protection (legal safeguards, guardianship, tutorship), persons deprived of their liberty, ...

Primary outcomes:
measure: presence or absence of malnutrition
timeFrame: The inclusion day
measure: Score EPA
timeFrame: The inclusion day
Secondary outcomes:
Other outcomes:
Locations:
city: Acigné
country: France
facility: Cabinet médical des Rosiers
city: Berné
country: France
facility: Cabinet médical des Docteurs Le Vagueres et Godard,
city: Languidic
country: France
facility: Cabinet médical du Dr Berthier,
Study officials:
affiliation: Rennes University Hospital
name: Ronan PhD Thibault
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06653361: Ultra-Widefield Fluorescein Angiography-Based Targeted Retinal Photocoagulation Versus Conventional Panretinal Photocoagulation in the Preservation of Visual Function and Regression of Proliferative Diabetic Retinopathy
Official title: Ultra-Widefield Fluorescein Angiography-Based Targeted Retinal Photocoagulation Versus Conventional Panretinal Photocoagulation in the Preservation of Visual Function and Regression of Proliferative Diabetic Retinopathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Proliferative Diabetic Retinopathy - High Risk
Keywords: Diabetic retinopathy
Laser photocoagulation
Fluorescein angiography
Lead sponsor: Hayatabad Medical Complex
Sponsor class: OTHER_GOV
Collaborators: name: Khyber Teaching Hospital
First posted: 2024-10-22
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Proliferative diabetic retinopathy is a vision-threatening disease that can lead to irreversible visual loss. The treatment options for proliferative diabetic retinopathy are anti-VEGF injection and retinal photocoagulation. The study aims to compare ultra-widefield fluorescein angiography-based targeted retinal photocoagulation and panretinal photocoagulation in the treatment of proliferative diabetic retinopathy.


Eligibility criteria: Inclusion Criteria:

* proliferative diabetic retinopathy (PDR) with neovascularization on the disc or elsewhere in the retina

Exclusion Criteria:

* Participants with a history of previous history of:
* retinal photocoagulation
* vitreoretinal surgery
* tractional retinal detachment
* epiretinal membrane
* vitreomacular traction
* glaucoma
* uveitis
* media opacities like cataract, corneal opacity, vitreous hemorrhage
* anti-VEGF injections in last 3 months

Primary outcomes:
measure: BCVA
timeFrame: 2 months
measure: CMT
timeFrame: 2 months
measure: MD
timeFrame: 2 months
measure: VFI
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: Khyber Teaching Hospital Peshawar
state: KP
Study officials:
References:
Clinical trial NCT04544761: Resilience in Persons Following Spinal Cord Injury
Official title: Resilience in People Following Spinal Cord Injury
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Spinal Cord Injuries
Keywords: Resilience
Lead sponsor: Shirley Ryan AbilityLab
Sponsor class: OTHER
Collaborators: name: Kiwanis Neurological Research Foundation
First posted: 2020-09-10
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Persons who have experienced spinal cord injury at least 1 year prior to enrollment

Brief summary: This study aims to quantify resilience in survivors of a spinal cord injury. The study will consist of structured interviews and self-reported surveys. We will look for common themes between participants at different stages of injury (1-5 years, 5-15 years, \>15 Years).

Detailed description: The goal of this project is to broaden the understanding of the lived experience of aging with a disability, from the perspectives of individuals with physical disabilities resulting from spinal cord injury (SCI). The specific objectives of this project are to:

1. Learn how people with SCI attain and maintain optimal quality of life as they age.
2. Understand how people with SCI develop resilience as they grow older.
3. Understand how individual quality of life is related to the degree and mechanism of resilience among people with SCI.
4. Learn which resources and practices have been most helpful and useful to people with SCI as they age with their disability.
5. Assess personal, behavioral, and environmental factors that contribute to resilience and quality of life among people aging with SCI.
6. Refine and confirm a holistic model for the relationships among the concepts of resilience, quality of life, and person-centered factors (resources, behaviors).

Through in-depth interviews and detailed surveys, we will explore how people with SCI attain and maintain optimal quality of life as they age, and how their quality of life relates to resiliency as they traverse the path of aging with SCI. We will explore with participants the resources and practices that have been most helpful and useful to them as they age with their disability.

Eligibility criteria: Inclusion Criteria:

* 18-80 years old
* History of Traumatic Spinal Cord Injury at least 1 year prior
* Ability to self-report on factors affecting health and well being Exclusion Criteria
* Progressive Spinal Cord Injury

Primary outcomes:
measure: Themes Survey
timeFrame: 1 day (Single time point)
Secondary outcomes:
measure: Resilience
timeFrame: 1 day (Single time point)
Other outcomes:
measure: Health Questionnaire Surveys
timeFrame: 1 day (Single time point)
Locations:
city: Chicago
country: United States
facility: Shirley Ryan AbilityLab
state: Illinois
Study officials:
affiliation: Shirley Ryan AbilityLab
name: Elliot Roth, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02230709: Immediate Effects of Dry Needling and Tens in Chronic Neck Pain
Official title: IMMEDIATE EFFECTS OF DRY NEEDLING VERSUS DRY NEEDLING AND TENS ON PAIN IN PATIENTS WITH CHRONIC MIOFASCIAL NECK PAIN
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Myofascial Neck Pain
Keywords: Neck pain
Myofascial pain syndrome
Soreness
Lead sponsor: Universidad Rey Juan Carlos
Sponsor class: OTHER
First posted: 2014-09-03
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 48
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determinate the effects of percutaneous electrical nerve stimulation in the short-term for pain in patients with myofascial chronic neck pain.


Eligibility criteria: Inclusion Criteria:

* Neck pain for more than six months of evolution.
* Active Myofascial Trigger Point number 2 on Trapezius muscle.
* Score of more than 2 points in a Visual Analog Scale.

Exclusion Criteria:

* Neck pain specific.
* Radiculopathies.
* Whiplash.
* Dizziness and migraines
* Cervical surgical intervention
* Previous treatment of Dry Needling

Primary outcomes:
measure: Neck Pain
timeFrame: 4 days
measure: Post-needling pain
timeFrame: 4 days
Secondary outcomes:
measure: Pressure Pain threshold
timeFrame: 4 days
measure: Range of Motion
timeFrame: 4 days
Other outcomes:
Locations:
city: Aravaca
country: Spain
facility: CSEU La Salle
state: Madrid
Study officials:
References: